Drug Profile

Litifilimab - Biogen

Alternative Names: 24F4A; Anti-BDCA2 antibody - Biogen; BIIB-059

Latest Information Update: 15 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biogen Idec
Developer Biogen
Class Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Cutaneous lupus erythematosus; Systemic lupus erythematosus

Most Recent Events

29 Mar 2026 Adverse events and efficacy data from the Part A portion of phase II/III AMETHYST trial in Cutaneous lupus erythematosus released by Biogen
10 Mar 2026 Biogen completes a phase I trial (In volunteers) in the US (SC, Injection) (NCT06741657)
28 Jan 2026 Litifilimab - Biogen receives Breakthrough Therapy status for Cutaneous lupus erythematosus in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com